Physio-pathological models

Myocardial infarction is a key component of cardiovascular disorders, which makes it the most prevalent CVD in the western world. Myocardial infarction leads to heart failure when it is inadequately managed. In this case, cardiac output is greatly reduced and the aetiology refers to heart failure with reduced ejection fraction.

Acute myocardial infarction, commonly known as a heart attack, is considered part of a spectrum referred to as acute coronary syndrome (ACS). Interruption of the blood supply to part of the heart leads to death or necrosis of myocardial cells when myocardial ischemia exceeds a critical threshold and overwhelms myocardial cellular repair mechanisms designed to maintain normal heart physiology.

Cardiac hypertrophy is a major predictor of many cardiovascular diseases including heart failure with ominous prognosis. Cardiac hypertrophy is an adaptive response usually driven by a larger workload through either biomechanical stretch‐sensitive mechanisms or neurohumoral activation. Our dedicated experimental models are instrumental in furthering the understanding of cardiac hypertrophy pathophysiology and evaluating drugs candidates.

Cardiomedex provides the gold standard pressure-overload model induced by controlled transverse aortic constriction (TAC), and the angiotensin-II induced hypertrophy model.

Aortic constriction – RatAortic constriction – MouseAngiotensin II – Mouse

Over the past few decades, there has been a dramatic increase in cardiometabolic complications including hyperlipidemia, dyslipidemia, obesity, type 2 diabetes, hypertension, nephropathy and non-alcoholic fatty liver disease not only in industrialized nations but also in developing nations with emerging economies. These cardiovascular and metabolic disorders, both individually and interdependently, have led to a substantial increase in CVD morbidity and mortality. The selective prevention of cardiometabolic complications could help reduce the burden of these diseases in the general population,

With this objective, Cardiomedex, in association with Physiogenex provides relevant models with concomitant risk factors with full cardiovascular characterization.

NASH – MouseHFpEF /Obesity – RatDiabetic nephropathy – Rat

Hypertension is the most common cardiovascular disease and can lead to lethal complications if left untreated. Indeed, hypertension is one of the highest risk factors for almost all the different cardiovascular diseases acquired during a person’s lifetime (coronary disease, left ventricular hypertrophy, renal failure…).

Experimental models (genetic, surgical or dietary) are provided for unraveling the pathogenesis of hypertension and for testing novel therapeutic strategies.

The anthracyclines, one of the most common classes of chemotherapeutic agents, have been widely associated with an increased risk of cardiac toxicity limiting their used as anticancer treatment.

For this purpose, we provide both acute and chronic models of doxorubicin cardiotoxicity to investigate cardioprotective effects of drug candidates.

Sepsis is a systemic inflammatory response that follows bacterial infection and can lead to severe sepsis and septic shock characterized by hypotension, ischemia, multiple organ failure, and death. Sepsis is a major health complication causing patient mortality and rising health care costs.

Animal models are currently in development to create reproducible systems for studying sepsis pathogenesis and preliminary testing of potential therapeutic agents.